Novavax and King in HPV vaccine deal

NOX granted KG an exclusive license to its cell line technology to develop recombinant human papillomavirus (HPV) virus-like particle (VLP) vaccines. NOX retains the right to co-market resulting products in the U.S., and will receive a 17 percent royalty. Under a contract with the National Cancer Institute, NOX has been working with KG on manufacturing HPV-16 VLP vaccines, which are being evaluated by the NCI in clinical trials to prevent or treat HPV-16-associated cervical cancer (see BioCentury, Oct. 16). Phase III testing of the HPV-16 L1 VLP vaccine is expected to begin in mid-2001. ...